Global Irritable Bowel Syndrome (IBS) Treatment Market to Reach USD 29.02 Billion by 2033, Growing at a CAGR of 9.8%

January 24, 2025 06:38 AM AEDT | By EIN Presswire
 Global Irritable Bowel Syndrome (IBS) Treatment Market to Reach USD 29.02 Billion by 2033, Growing at a CAGR of 9.8%
Image source: EIN Presswire

Irritable Bowel Syndrome (IBS) treatment is projected to expand significantly, growing from USD 12.51 billion in 2024

VANCOUVER, BRITISH COLUMBIA, CANADA, January 24, 2025 /EINPresswire.com/ -- Emergen Research's latest market research report, titled Global Irritable Bowel Syndrome Treatment Market, provides estimated market size and shares, latest industry trends, global market growth rates, key drivers and opportunities, constraints, product segmentation, and major market players. Cost structure, market size, competitive landscape, product portfolio and specifications, and company profiles.

The global market for Irritable Bowel Syndrome (IBS) treatment is projected to expand significantly, growing from USD 12.51 billion in 2024 to USD 29.02 billion by 2033 at an impressive CAGR of 9.8%. This growth is driven by the increasing prevalence of IBS worldwide, advancements in diagnostic tools, and the development of personalized treatment options.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), IBS affects 10–15% of the global population, with many cases remaining undiagnosed. In the U.S. alone, IBS accounts for approximately 12% of annual primary care visits, placing a notable burden on healthcare systems. Organizations such as the World Gastroenterology Organisation (WGO) are working to raise global awareness about the importance of early diagnosis and effective management to improve patient outcomes. Initiatives like "World Digestive Health Day" highlight efforts to educate the public and healthcare providers about gastrointestinal disorders, including IBS.

Get Free Sample PDF Copy Of This Report At: https://www.emergenresearch.com/request-sample/3302

Government-backed research is also accelerating the development of new therapies. For instance, the U.S. National Institutes of Health (NIH) has funded studies on gut-brain axis interactions, leading to innovative treatments like serotonin-based drugs and dietary interventions. This focus on reducing the socioeconomic impact of IBS—such as lost productivity and healthcare costs—is expected to further drive investments in research and public health initiatives.

Advancements in Diagnostics and Personalized Medicine Propel Market Growth

Technological advancements in diagnostic tools and personalized medicine are transforming IBS treatment. Non-invasive techniques such as fecal calprotectin tests, lactulose breath tests, and advanced imaging methods have improved the accuracy of IBS diagnoses. These tools are endorsed by organizations like the National Institute for Health and Care Excellence (NICE) for distinguishing IBS from other gastrointestinal conditions, enabling faster and more precise treatment.

Personalized medicine is also paving the way for innovative therapies tailored to individual patients. Research by institutions like the NIH and the European Medicines Agency (EMA) has led to microbiome-focused treatments, including probiotics, prebiotics, and fecal microbiota transplantation (FMT). A 2022 NIH report highlighted the effectiveness of these precision therapies, which not only improve symptom control but also minimize side effects, making IBS treatments more patient-centric and effective.

Challenges in Understanding IBS Pathophysiology Could Limit Growth

Despite these advancements, the market faces challenges due to limited understanding of IBS’s complex pathophysiology. Factors such as gut-brain axis dysfunction, microbiota imbalances, and environmental triggers contribute to IBS, but no single definitive cause has been identified. This knowledge gap hinders the development of targeted therapies and biomarkers.

Request For Customization: https://www.emergenresearch.com/request-for-customization/3302

Competitive Terrain:

The global Irritable Bowel Syndrome Treatment industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

Leading Market Players Profiled in the Report:

Ironwood Pharmaceuticals, Inc.

Allergan

Astellas Pharma, Inc.

Takeda Pharmaceutical Company Limited

AstraZeneca

Sanofi S.A.

Sebela Pharmaceuticals Inc.

Bausch Health

Synthetic Biologics, Inc.

Ardelyx

Key reasons to buy the Global Irritable Bowel Syndrome Treatment Market report:

The latest report comprehensively studies the global Irritable Bowel Syndrome Treatment market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.

The report offers an insightful analysis of the regional outlook of the market.

It offers a detailed account of the end-use applications of the products & services offered by this industry.

The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.

The global Irritable Bowel Syndrome Treatment market report covers the analysis of drivers, trends, limitations, restraints, and challenges arising in the Irritable Bowel Syndrome Treatment market. The report also discusses the impact of various other market factors affecting the growth of the market across various segments and regions. The report segments the market on the basis of types, applications, and regions to impart a better understanding of the Irritable Bowel Syndrome Treatment market.

Irritable Bowel Syndrome Treatment Market Segmentation Analysis

Type Outlook (Revenue, USD Billion; 2020-2033)

IBS-C

IBS-D

Drug Class Outlook (Revenue, USD Billion; 2020-2033)

Xifaxan

Linzess/Constella

Viberzi

Amitiza

Others

Distribution Channel Outlook (Revenue, USD Billion; 2020-2033)

Hospital Pharmacy

Retail Pharmacy

Others

Browse Full Report@ https://www.emergenresearch.com/industry-report/irritable-bowel-syndrome-treatment-market

Regional Outlook:

North America (the U.S., Canada, Mexico)

Europe (the U.K., Germany, France, Italy)

Asia Pacific (India, China, Japan, Korea)

Latin America (Brazil, Argentina, Ecuador, Chile)

Middle East & Africa (Egypt, Turkey, Saudi Arabia, Iran)

The study will prove useful for leading companies looking to find new sources of income by helping them to understand the market and its underlying dynamics. It will also be useful for businesses looking to expand into new markets or diversify their current operations.

How will this Report Benefit you?

An Emergen Research report of 250 pages contains 194 tables, 189 charts and graphics, and anyone who needs a comprehensive analysis of the global Irritable Bowel Syndrome Treatment market, as well as commercial, in-depth analyses of the individual segments, will find the study useful. Our recent study allows you to assess the entire regional and global market for Irritable Bowel Syndrome Treatment. In order to increase market share, obtain financial analysis of each segment and the whole market.

Look at how you can utilize the current and potential revenue-generating opportunities available in this sector. We believe that there are significant prospects for energy storage technology in this industry due to the rapid expansion of the technology. In addition to helping you build growth strategies, improve competitor analysis, and increase business productivity, the research will also assist you in making better strategic decisions.

Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.

Eric Lee
Emergen Research
+ +91 90210 91709
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.